To see if you qualify call:

1-877-777-9228

or visit us online at wcct.com

This clinical trial will be held in Tempe, Arizona

2420 W Baseline Rd.

Tempe, AZ 85283

cforms contact form by delicious:days

cforms contact form by delicious:days

WCCT Global
Please call: 1-877-777-9228

cforms contact form by delicious:days

WCCT Global

Please call: 1-877-777-9228

cforms contact form by delicious:days

Cypress, California and San Francisco – January 10, 2012 – West Coast Clinical Trials, LLC (WCCT), a contract research organization (CRO) supporting early phase biopharmaceutical and device development, today announced it has received a substantial equity investment from Housatonic Partners, a $1 billion San Francisco-based private equity firm with expertise in the healthcare and pharmaceutical services markets. Terms of the investment were not disclosed.

WCCT Global specializes in complex Phase I-IIa special population studies, which assess a drug’s efficacy and dosage requirements within a particular subset of a larger population. The company has extensive expertise in protocol design, volunteer enrollment, and management of ethno-bridging, thorough QTc (important cardiac safety parameter), respiratory, infectious disease, pediatric, post-menopausal and renal trials.

Mark Hilderbrand, Managing Director of Housatonic, said, “Thanks to Founder and CEO Dr. Kenneth Kim and the management team, WCCT Global is well positioned for continued growth. They have grown this business annually, even through the difficult and turbulent economy of the last three years. This impressive accomplishment gives us confidence that this team is the right one to guide the company through its next stage of growth and development.”

Added Hilderbrand, “We also are pleased to announce that Ken will assume the role of Chairman of the Board in addition to CEO. We look forward to working with WCCT Global on its global expansion plans.”

Said Dr. Kim, “Support from Housatonic will enable us to more rapidly achieve our goal of becoming a full-service provider of early stage R&D services to internationally recognized pharmaceutical and device manufacturers. Given our future expansion plans, we have renamed the company WCCT Global and appointed a Board of Directors. Our management team is looking forward to working with Housatonic and our stellar Board to build a premier early drug development CRO that will serve biotechs and pharma companies worldwide.”

The newly formed WCCT Global Board of Directors includes the following people:

Dr. Kenneth Kim, MD, Chairman, Founder and CEO, WCCT Global

Dr. Kim is the founder and CEO of West Coast Clinical Trials, LLC (now WCCT Global).   He has been a principal, sub-investigator, or medical safety officer in over 400 phase 1 trials and worked as a consultant to Pharma and regulators worldwide on drug development and study design strategies in the areas of ethnobridging, cardiac safety, and pediatric trial study programs.  Dr. Kim completed his undergraduate and medical training at Harvard University, and his internal medicine and allergy/immunology fellowship at UCLA.  He is board certified in both internal medicine and allergy/immunology and is on the clinical faculty at UCLA.

Craig Albright
Craig Albright has been an operating executive in several healthcare industry sectors and active in the healthcare private equity community for nearly two decades. He has served as CEO of Gentiae Clinical Research and Free & Clear, Inc., and as interim CEO of NVision, Inc. Albright also serves on the Board of Directors of U.S. HealthWorks, Inc.

Mark G. Hilderbrand
Mark Hilderbrand has been a Managing Director at Housatonic Partners since 2006 and has more than 16 years of experience in private equity. Prior to Housatonic, he was a General Partner at Onset Ventures and worked at Summit Partners, where he focused on recapitalizations and buyouts of high-growth technology and services businesses.

Helen Kim
Helen Kim currently serves on the Board of Directors at Sunesis Pharmaceuticals and at ImmunoCellular Therapeutics. She also serves as the Chief Business Officer of NGM Biopharmaceuticals, a privately held drug discovery company. Previously, Kim was President and CEO of Kosan Biosciences Inc., where she restructured and repositioned the company prior to its acquisition by Bristol-Myers Squibb.

Bill Taaffe
Bill Taaffe retired from ICON Clinical Research in June 2011 after 40 years in the pharmaceutical and CRO industry. He was one of the founding members of ICON, PLC where he held the position of President and Chief Executive Officer, North America. Prior to ICON, Taaffe spent two years with Circa Pharmaceuticals, two years with Bioresearch and 18 years with The Institute of Clinical Pharmacology where he served as Chief Executive Officer, USA.

About WCCT Global
WCCT Global is a global provider of outsourced early drug development services to the pharmaceutical, biotechnology and medical device industries.  As a drug development partner, WCCT Global partners with domestic and foreign innovator companies who need regulatory, program management, and strategic consulting support from First-in-Man thru the proof of concept stage with an emphasis on overseeing and executing on trials in special disease populations, ethnobridging volunteers, and cardiac safety studies.  Visit WCCT Global on the web at http://www.wcctglobal.com.

About Housatonic
Housatonic Partners is a private equity investment firm founded in 1994 with $1 billion in capital under management. The firm focuses on buyouts and recapitalizations of rapidly growing, profitable service businesses with highly recurring revenue. In partnership with exceptional management, Housatonic has led investments in more than 60 small to mid-sized companies. Visit Housatonic on the web at http://www.housatonicpartners.com.

Contact for WCCT Global
Talia Nikolao
Executive Director, Business Development
talia.nikolao@wcct.com

714-668-1500
Contact for Housatonic
William Kuntz
Vice President
wkuntz@housatonicpartners.com

415-955-9020

To see if you qualify call:

1-877-777-9228

or visit us online at wcct.com

This clinical trial will be held in Anniston, Alabama

Anniston, AL   36207

1. Your Name(required)
2. Phone number
3. Email(valid email required)
4. Message

 

cforms contact form by delicious:days

Cypress, CA, September 29, 2011

West Coast Clinical Trials, LLC (WCCT) is pleased to announce the publication of  the ethnobridging Pharmacokinetic-Pharmacodynamic study of the novel, orally bioavailable, anti-platelet drug, vorapaxar, carried out in collaboration with Merck, Sharp and Dohme Corp (Eur J Clin Pharmacol DOI 10.1007/s00228-011-1127). Vorapaxar is now in late Phase III clinical development for the prevention and treatment of atherothrombotic disease.  WCCT carried out the clinical portion of this important trial which demonstrated that vorapaxar produced rapid, complete, and sustained inhibition of TRAP-induced platelet aggregation when administered as a single dose of 40 mg or as multiple once-daily 2.5 mg doses with no apparent differences between Japanese and Caucasian subjects. 

About WCCT

WCCT is an early phase drug development clinical CRO, based in the United States with 150 beds in 2 locations.  As a drug development partner, WCCP Global works with domestic and foreign innovator companies who need regulatory and strategic development support from First-in-Man thru the proof of concept stage. WCCT Global specializes in special patient population phase I studies that require complex study designs and procedures, including thorough QTc and ethnobridging studies.

Contact: mgr@wcct.com for more information

Cypress, CA, November 5, 2011

West Coast Clinical Trials, LLC (WCCT) is pleased to announce the presentation of results of a Hypothalamic-Pituitary- Adrenal Axis function study in children ages 2 – 11 years of age with Allergic Rhinitis.  One hundred thirty-two (132)  children completed the trial.  The children were treated with either NASACORT® AQ nasal spray or placebo for 6 weeks.  No significant treatment effect compared to placebo was observed.  WCCT  was the highest enrolling site of the 3 centers chosen to carry out this important trial.  

About ACAAI
The ACAAI is a professional association of 5,000 allergists/immunologists. Established in 1942, the ACAAI is dedicated to improving the quality of patient care in allergy and immunology through research, advocacy and professional public education.
Contact: mgr@wcct.com for more information

About WCCT

WCCT is a privately owned early phase development contract research organization, conveniently located near 3 major airports in Southern California. WCCT was founded by Dr. Kenneth Kim who is board certified in Internal Medicine and Allergy and Immunology. Conducting trials since 1998, WCCT has been audited by the FDA and numerous pharmaceutical and biotechnology companies. WCCT’s location and access to an ethnically diverse population allows for a wide variety of study designs including ethnic bridging. With 150 beds in two locations and over 60,000 square feet, a well-trained and experienced staff, and advanced technological procedures, WCCT brings the highest quality to the pharmaceutical and biotechnology industries. (www.wcct.com)

Contact

West Coast Clinical Trials, LLC

Business Development  1-714.252.0783

mgr@wcct.com

About BioKorea:
“BIO KOREA” launched by the Korean government aims to vitalize the bio industry and make Korea one of the top five world bio players by 2016. Marking its sixth anniversary. this year, BIO KOREA cemented itself as a world class bio event. Many Korean major policy makers, government employees, bio industry managers, and domestic and international experts to participated in the conference.

About WCCT

WCCT is a privately owned early phase development contract research organization, conveniently located near 3 major airports in Southern California. WCCT was founded by Dr. Kenneth Kim who is board certified in Internal Medicine and Allergy and Immunology. Conducting trials since 1998, WCCT has been audited by the FDA and numerous pharmaceutical and biotechnology companies. WCCT’s location and access to an ethnically diverse population allows for a wide variety of study designs including ethnic bridging. With 150 beds in two locations and over 60,000 square feet, a well-trained and experienced staff, and advanced technological procedures, WCCT brings the highest quality to the pharmaceutical and biotechnology industries. (www.wcct.com)

Contact

West Coast Clinical Trials, LLC

Business Development  1-714.252.0783

mgr@wcct.com

This was a phase IV study to characterize the effect of TAA-AQ 110 µg once daily on basal HPA axis function in children. Methods: This was a multicenter, randomized, double-blind, placebo-controlled, parallel-group study.

Main inclusion criteria were age ≥2 to 11 years, documented diagnosis of seasonal or perennial allergic rhinitis by history and positive skin prick test, with ≥1 nasal symptom (nasal pruritus, sneezing rhinorrhea, or congestion) rated ≥1 on a 0-3 scale, and a morning serum cortisol within 5 – 22 µg/dL at Visit 1. Protocol approval was obtained from Schulman Associates IRB. Written informed consents were obtained from parents/legal guardians and assent from the participants. Following a brief single-blind placebo run-in period, subjects were randomized by age group and sex strata to receive TAA-AQ (55 µg of TAA/spray) 1 spray/nostril (children ≥2 to 11 years of age) or 2 sprays/nostril (children ≥6 to 11 years of age) or matching placebo for 42 to 47 days. Subjects underwent 2 domiciled visits to assess 24hr serum cortisol pre- and post- treatment, and recorded daily nasal symptom scores.

About WCCT

WCCT is a privately owned early phase development contract research organization, conveniently located near 3 major airports in Southern California. WCCT was founded by Dr. Kenneth Kim who is board certified in Internal Medicine and Allergy and Immunology. Conducting trials since 1998, WCCT has been audited by the FDA and numerous pharmaceutical and biotechnology companies. WCCT’s location and access to an ethnically diverse population allows for a wide variety of study designs including ethnic bridging. With 150 beds in two locations and over 60,000 square feet, a well-trained and experienced staff, and advanced technological procedures, WCCT brings the highest quality to the pharmaceutical and biotechnology industries. (www.wcct.com)

Contact

West Coast Clinical Trials, LLC

Business Development  1-714.252.0783

mgr@wcct.com